Epilepsy – UCB EP0162
Participating in a clinical trial with Profound means making a real difference in the lives of others facing similar health challenges.
The purpose of the study is to assess the success of a single administration of Staccato alprazolam compared with placebo both in rapidly terminating a seizure episode within 90 seconds and with no recurrence of seizure(s) up to 2 hours after investigational medicinal product (IMP) administration.
Inclusion Criteria:
- Participant must be ≥12 years of age at the Baseline/Randomization Visit
- Participant must have a study caregiver ≥18 years of age at the Screening Visit
- Participants with an established diagnosis of focal or generalized epilepsy or combined focal and generalized epilepsy with a documented history of stereotypical episodes of prolonged seizures
- Other criteria may apply
Complete the form to get connected with new research studies and our team will reach out soon to help determine your eligibility.
